PUBLISHER: Grand View Research | PRODUCT CODE: 1405770
PUBLISHER: Grand View Research | PRODUCT CODE: 1405770
The global bioelectric medicine market size is expected to reach USD 35.42 billion by 2030, registering a CAGR of 6.1% from 2023 to 2030, according to a new report by Grand View Research, Inc. The key factors driving the market include the rising geriatric population, strategic initiatives by key companies, and increasing investment in R&D for advanced electroceuticals/ bioelectric medicines. In April 2022, Cochlear agreed to acquire Demant's hearing implants business - Oticon Medical. This would enable the company to increase its R&D investments and market growth activities and provide it with greater scale.
In 2021, around 20.8% or more than one-fifth of the population in the EU was aged 65 and over, according to Eurostat. The aging population is prone to medical disorders such as Alzheimer's disease, epilepsy, cardiac arrhythmias, Parkinson's disease, and depression. Hence, this is a key factor contributing to the market growth. Advanced bioelectronic devices including cochlear implants, implantable cardioverter defibrillators, cardiac pacemakers, and spinal cord stimulators are used for the treatment of these conditions.
Growing investments in the R&D of advanced electroceuticals is another major factor supporting the growth of the market. For example, in 2021, Medtronic invested around USD 2.5 billion in R&D for the development of advanced products. According to ElectroCore, almost 325,000 people in the U.S. experience cluster headaches every year. The company capitalized on the opportunity by developing a product called gammaCore, which received FDA clearance in 2018. The product is indicated for non-invasive VNS therapy helpful in managing painful headaches in adults.